Avalo Q3 net loss misses estimates, LOTUS trial enrollment complete

Reuters11-06

Avalo Q3 net loss misses estimates, LOTUS trial enrollment complete

Overview

Avalo Therapeutics Q3 net loss misses analyst expectations
Operating expenses rose due to Phase 2 LOTUS trial costs
Completed enrollment for Phase 2 LOTUS trial; data expected mid-2026

Outlook

Avalo expects cash reserves to fund operations into 2028
Topline data from Phase 2 LOTUS trial expected mid-2026

Result Drivers

R&D EXPENSES - Increased R&D expenses driven by Phase 2 LOTUS trial costs
LEADERSHIP EXPANSION - Expanded leadership team with key appointments in business development and HR

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income	Miss	-$30.63 mln	-$18.75 mln (8 Analysts)
Q3 Pretax Profit	Miss	-$30.61 mln	-$18.77 mln (7 Analysts)
Q3 Operating Expenses		$19.20 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Avalo Therapeutics Inc is $35.00, about 53% above its November 5 closing price of $16.45

Press Release: ID:nGNX4DRgXz

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581067246?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581067246","market":"us","top_or_hot":-1,"title":"Avalo Q3 net loss misses estimates, LOTUS trial enrollment complete","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Avalo Q3 net loss misses estimates, LOTUS trial enrollment complete</title></head><body><p><span>Overview</span></p><ul><li><p>Avalo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss misses analyst expectations</p></li><li><p>Operating expenses rose due to Phase 2 LOTUS trial costs</p></li><li><p>Completed enrollment for Phase 2 LOTUS trial; data expected mid-2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Avalo expects cash reserves to fund operations into 2028</p></li><li><p>Topline data from Phase 2 LOTUS trial expected mid-2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Increased R&amp;D expenses driven by Phase 2 LOTUS trial costs</p></li><li><p>LEADERSHIP EXPANSION - Expanded leadership team with key appointments in business development and HR</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Miss</p></td><td><p>-$30.63 mln</p></td><td><p>-$18.75 mln (8 Analysts)</p></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td><p>Miss</p></td><td><p>-$30.61 mln</p></td><td><p>-$18.77 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$19.20 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/AVTX\">Avalo Therapeutics Inc</a> is $35.00, about 53% above its November 5 closing price of $16.45</p></li></ul><p>Press Release: <span>ID:nGNX4DRgXz</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avalo Q3 net loss misses estimates, LOTUS trial enrollment complete</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvalo Q3 net loss misses estimates, LOTUS trial enrollment complete\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Avalo Q3 net loss misses estimates, LOTUS trial enrollment complete</title></head><body><p><span>Overview</span></p><ul><li><p>Avalo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss misses analyst expectations</p></li><li><p>Operating expenses rose due to Phase 2 LOTUS trial costs</p></li><li><p>Completed enrollment for Phase 2 LOTUS trial; data expected mid-2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Avalo expects cash reserves to fund operations into 2028</p></li><li><p>Topline data from Phase 2 LOTUS trial expected mid-2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Increased R&amp;D expenses driven by Phase 2 LOTUS trial costs</p></li><li><p>LEADERSHIP EXPANSION - Expanded leadership team with key appointments in business development and HR</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Miss</p></td><td><p>-$30.63 mln</p></td><td><p>-$18.75 mln (8 Analysts)</p></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td><p>Miss</p></td><td><p>-$30.61 mln</p></td><td><p>-$18.77 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$19.20 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/AVTX\">Avalo Therapeutics Inc</a> is $35.00, about 53% above its November 5 closing price of $16.45</p></li></ul><p>Press Release: <span>ID:nGNX4DRgXz</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0LG:1","article_id":"2581067246","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581067246","pubTimestamp":1762431500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Avalo Q3 net loss misses estimates, LOTUS trial enrollment completeOverviewAvalo Therapeutics Q3 net loss misses analyst expectationsOperating expenses rose due to Phase 2 LOTUS trial costsCompleted e","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AVTX":"Avalo Therapeutics Inc"},"translate_title":"Avalo第三季度净亏损未达预期，LOTUS试验注册完成","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVTX":0.9},"content_text":"Avalo Q3 net loss misses estimates, LOTUS trial enrollment completeOverviewAvalo Therapeutics Q3 net loss misses analyst expectationsOperating expenses rose due to Phase 2 LOTUS trial costsCompleted enrollment for Phase 2 LOTUS trial; data expected mid-2026OutlookAvalo expects cash reserves to fund operations into 2028Topline data from Phase 2 LOTUS trial expected mid-2026Result DriversR&D EXPENSES - Increased R&D expenses driven by Phase 2 LOTUS trial costsLEADERSHIP EXPANSION - Expanded leadership team with key appointments in business development and HRKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net IncomeMiss-$30.63 mln-$18.75 mln (8 Analysts)Q3 Pretax ProfitMiss-$30.61 mln-$18.77 mln (7 Analysts)Q3 Operating Expenses$19.20 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Avalo Therapeutics Inc is $35.00, about 53% above its November 5 closing price of $16.45Press Release: ID:nGNX4DRgXzFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581067246","isCrawlerRequest":true}